Achieve Life Sciences (ACHV) Q1 2023: Cytisinicline Triples Vaping Quit Odds, Setting Up NDA Milestone
Cytisinicline delivered breakthrough results in vaping cessation, tripling quit odds versus placebo and expanding Achieve's addressable market. Operating expenses peaked with two trials completing, while preparations for NDA submission and potential label expansion accelerate. Upcoming ORCA-3 Phase III data and regulatory milestones will define Achieve’s near-term trajectory and commercial prospects.
Summary
- Vaping Opportunity Validated: Cytisinicline’s Phase II data positions Achieve as a first-mover in vaping cessation.
- Pipeline Execution: Dual trial completions and NDA-enabling studies support regulatory momentum.
- Regulatory Inflection Ahead: ORCA-3 Phase III results and NDA timing will shape the next phase of value creation.
Business Overview
Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing cytisinicline, a plant-derived nicotinic acetylcholine receptor agonist for use in smoking and nicotine cessation. The company generates value by advancing cytisinicline through late-stage clinical development, targeting both traditional smoking and the rapidly growing vaping cessation markets. Key business segments include clinical trial execution, regulatory advancement, and prospective commercialization in partnership with contract manufacturers and potential commercial partners.
Performance Analysis
Achieve’s first quarter was defined by clinical execution and a pivotal expansion of addressable market opportunity. The company reported positive topline results from the ORCAv1 Phase II trial, the first randomized placebo-controlled study for vaping cessation, in which cytisinicline demonstrated a statistically significant benefit. Subjects receiving cytisinicline were approximately three times more likely to quit vaping than placebo, with a 31.8% continuous abstinence rate over the final four weeks of treatment versus 15.1% for placebo.
Operating expenses peaked at $8.6 million, reflecting the simultaneous completion of ORCA-3 (Phase III) and ORCAv1 (Phase II) trials. This marks a high point in R&D spend, with management guiding for costs to decline as trial activity winds down. The company ended the quarter with $16.6 million in cash, providing runway into late 2023. Management cited a one-time stock-based compensation grant as a driver of G&A expense uptick, clarifying that underlying expense trends should normalize in coming quarters.
- Vaping Indication Expansion: ORCAv1 data opens a new, high-growth segment for cytisinicline beyond smoking cessation.
- Cash Runway and Spend: Sufficient liquidity into late 2023, with spending expected to decline post-trial completion.
- Regulatory Preparation: NDA-enabling studies and CMC (Chemistry, Manufacturing, Controls) readiness are on-track for 2023 completion.
With both clinical studies completed and regulatory filings approaching, Achieve’s operational focus is shifting from trial execution to NDA preparation and commercial groundwork.
Executive Commentary
"Cytosinicline treatment resulted in a statistically significant benefit for nicotine e-cigarette cessation compared to placebo... we believe that cytosinicline has a unique opportunity to become a solution to help address this growing vaping epidemic."
John Binsich, Chief Executive Officer
"The primary endpoint results for vaping cessation showed subjects who received cytosinicline had 2.6 times higher odds or likelihood to quit vaping during the last four weeks of treatment compared to subjects who received placebo."
Dr. Cindy Jacobs, President and Chief Medical Officer
Strategic Positioning
1. First-Mover in Vaping Cessation
Achieve is positioned to lead the emerging market for vaping cessation therapeutics, validated by ORCAv1’s statistically significant results and strong demand signals from survey data (73% of e-cigarette users want to quit within 12 months). With no FDA-approved pharmacotherapy for vaping, cytisinicline could address an unmet need among 11 million U.S. adults and 2.5 million youth e-cigarette users.
2. Regulatory and NDA Readiness
The company is executing NDA-enabling activities on parallel tracks: completing three Phase I studies (PK in renal impairment, steady-state PK, TQT study), preparing for an FDA pre-NDA meeting in Q3, and advancing CMC and supply chain readiness with SoPharma. These steps are critical for both initial smoking cessation and subsequent vaping label expansion.
3. Commercialization and Market Access Foundations
Achieve is laying groundwork for market entry by progressing supply chain, packaging, and market access planning. The Affordable Care Act’s mandate for coverage of FDA-approved cessation products could support payer adoption, but management recognizes the need for proactive contracting and stakeholder engagement. Early brand name clearance and labeling work are underway to accelerate post-approval launch.
4. Board Refresh and Strategic Depth
Recent board additions bring expertise in capital markets, strategic transactions, and manufacturing, signaling readiness for late-stage development and potential commercial transition. This refresh may also improve Achieve’s negotiating leverage in partnering discussions.
Key Considerations
This quarter marks a strategic inflection, as Achieve transitions from development-stage execution to regulatory and commercial preparation. Investors should weigh the following:
Key Considerations:
- Vaping Market Growth: CDC data confirms rising e-cigarette use, expanding the potential market for cytisinicline beyond traditional smoking cessation.
- Regulatory Milestones: ORCA-3 Phase III results and NDA timing are pivotal; success could unlock both initial and expanded indications.
- Label Expansion Pathway: Management expects a single Phase III study may suffice for vaping approval, leveraging existing smoking cessation data to accelerate indication expansion.
- Debt Refinancing Needs: With debt maturity looming, positive lender discussions are underway, but refinancing remains a key watchpoint for liquidity.
Risks
Achieve faces regulatory, operational, and financial risks as it approaches NDA submission. Delay or negative results from ORCA-3 would materially impact timelines and market opportunity. Cash runway extends only into late 2023, making successful debt refinancing or new capital critical. Manufacturing and supply chain readiness, while progressing, remain potential bottlenecks if not fully validated pre-approval. Competition from entrenched smoking cessation products and payer adoption hurdles could affect uptake, despite favorable regulatory mandates.
Forward Outlook
For Q2 2023, Achieve expects:
- ORCA-3 Phase III topline data readout in the second half of the quarter
- Completion of NDA-enabling Phase I studies by year-end
For full-year 2023, management is focused on:
- Requesting and conducting a pre-NDA meeting with the FDA in Q3
- Finalizing CMC and supply chain readiness for NDA submission
Management highlighted that operating expenses will decline as clinical trials wind down and that NDA submission is targeted for the first half of 2024, contingent on successful ORCA-3 results and completion of required studies.
- Board refresh and commercialization planning are expected to accelerate in parallel with regulatory milestones.
- Debt refinancing discussions are ongoing, with positive lender engagement but no finalized terms yet.
Takeaways
Investors should focus on Achieve’s ability to convert clinical validation into regulatory and commercial milestones.
- Vaping Data Validates Growth Thesis: ORCAv1 results establish cytisinicline as a first-in-class candidate for vaping cessation, broadening addressable market.
- Execution on Multiple Fronts: Clinical, regulatory, and operational tracks are converging toward NDA submission, with risk concentrated in ORCA-3 results and cash runway.
- Watch NDA Timing and Debt: The next two quarters are critical for regulatory clarity and liquidity; investors should monitor both FDA interactions and refinancing outcomes.
Conclusion
Achieve Life Sciences enters a pivotal phase, with breakthrough vaping cessation data and imminent Phase III results positioning cytisinicline for regulatory submission and potential first-mover advantage. Execution on NDA-enabling activities and financial flexibility will determine the company’s ability to capitalize on expanding market demand.
Industry Read-Through
Achieve’s results spotlight the emergence of vaping cessation as a distinct, high-growth therapeutic category. The lack of FDA-approved pharmacotherapy for e-cigarette users is a sector-wide gap, and Achieve’s clinical progress may accelerate competitive R&D and regulatory focus across the addiction therapeutics landscape. Broader industry players should note the importance of rapid trial enrollment, payer coverage mandates, and the operational complexity of label expansion for new indications. As vaping rates rise, expect increased investment, M&A interest, and regulatory scrutiny in nicotine cessation and adjacent behavioral health categories.